AR040021A1 - (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion - Google Patents
(s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacionInfo
- Publication number
- AR040021A1 AR040021A1 ARP030101702A ARP030101702A AR040021A1 AR 040021 A1 AR040021 A1 AR 040021A1 AR P030101702 A ARP030101702 A AR P030101702A AR P030101702 A ARP030101702 A AR P030101702A AR 040021 A1 AR040021 A1 AR 040021A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- chloro
- amino
- pharmaceutical composition
- tetrahidrofuril
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- MMAHZLJRNLZQCI-NRFANRHFSA-N 4-amino-5-chloro-2-methoxy-n-[1-[[1-[(2s)-oxolane-2-carbonyl]piperidin-4-yl]methyl]piperidin-4-yl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC2CCN(CC2)C(=O)[C@H]2OCCC2)CC1 MMAHZLJRNLZQCI-NRFANRHFSA-N 0.000 abstract 1
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000002325 prokinetic agent Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002141262 | 2002-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040021A1 true AR040021A1 (es) | 2005-03-09 |
Family
ID=29267809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101702A AR040021A1 (es) | 2002-05-16 | 2003-05-15 | (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6696468B2 (enExample) |
| EP (1) | EP1362857B1 (enExample) |
| JP (1) | JP3643107B2 (enExample) |
| KR (1) | KR20040107520A (enExample) |
| CN (1) | CN1653063A (enExample) |
| AR (1) | AR040021A1 (enExample) |
| AT (1) | ATE273304T1 (enExample) |
| AU (1) | AU2003230245A1 (enExample) |
| BR (1) | BR0309933A (enExample) |
| CA (1) | CA2483368A1 (enExample) |
| CZ (1) | CZ20041084A3 (enExample) |
| DE (1) | DE60300021T2 (enExample) |
| DK (1) | DK1362857T3 (enExample) |
| ES (1) | ES2227500T3 (enExample) |
| HU (1) | HUP0501016A2 (enExample) |
| IL (1) | IL165012A0 (enExample) |
| MX (1) | MXPA04011332A (enExample) |
| NO (1) | NO20045469L (enExample) |
| PL (1) | PL372724A1 (enExample) |
| PT (1) | PT1362857E (enExample) |
| RU (1) | RU2004136853A (enExample) |
| SK (1) | SK50192004A3 (enExample) |
| TR (1) | TR200403020T2 (enExample) |
| TW (1) | TW200400186A (enExample) |
| WO (1) | WO2003097638A1 (enExample) |
| ZA (1) | ZA200409053B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| DE602005016446D1 (de) * | 2004-11-05 | 2009-10-15 | Theravance Inc | 5-HT4-Rezeptoragonistenverbindungen |
| ES2327142T3 (es) * | 2004-11-05 | 2009-10-26 | Theravance, Inc. | Compuestos de quinolinona-carboxamida. |
| ES2347265T3 (es) * | 2004-12-22 | 2010-10-27 | Theravance, Inc. | Compuestos de indazol-carboxamida. |
| EP1871772B1 (en) * | 2005-03-02 | 2014-09-10 | Theravance, Inc. | Quinolinone compounds as 5-ht4 receptor agonists |
| US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| US20080200505A1 (en) * | 2005-05-27 | 2008-08-21 | Astrazeneca Ab | Piperidines for the Treatment of Chemokine Mediated Diseases |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| TWI423967B (zh) * | 2008-02-21 | 2014-01-21 | Dainippon Sumitomo Pharma Co | 醯胺衍生物及含有其之醫藥組合物 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| EA201491990A1 (ru) | 2012-05-03 | 2015-02-27 | Новартис Аг | L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH111472A (ja) | 1996-04-30 | 1999-01-06 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体及びそれを含有する医薬組成物 |
| DE69922186T2 (de) * | 1998-04-28 | 2005-05-04 | Dainippon Pharmaceutical Co., Ltd. | 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung |
| JP2000080081A (ja) | 1998-06-24 | 2000-03-21 | Dainippon Pharmaceut Co Ltd | １―〔（１―置換―４―ピペリジニル）メチル〕―４―ピペリジン誘導体及びそれを含有する医薬組成物 |
| JP2001122784A (ja) | 1999-10-27 | 2001-05-08 | Dainippon Pharmaceut Co Ltd | １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬 |
-
2002
- 2002-12-18 US US10/321,615 patent/US6696468B2/en not_active Expired - Fee Related
-
2003
- 2003-01-03 DE DE60300021T patent/DE60300021T2/de not_active Expired - Fee Related
- 2003-01-03 PT PT03250050T patent/PT1362857E/pt unknown
- 2003-01-03 ES ES03250050T patent/ES2227500T3/es not_active Expired - Lifetime
- 2003-01-03 DK DK03250050T patent/DK1362857T3/da active
- 2003-01-03 EP EP03250050A patent/EP1362857B1/en not_active Expired - Lifetime
- 2003-01-03 AT AT03250050T patent/ATE273304T1/de not_active IP Right Cessation
- 2003-05-08 TW TW092112525A patent/TW200400186A/zh unknown
- 2003-05-15 BR BR0309933-4A patent/BR0309933A/pt not_active Application Discontinuation
- 2003-05-15 CA CA002483368A patent/CA2483368A1/en not_active Abandoned
- 2003-05-15 JP JP2003137413A patent/JP3643107B2/ja not_active Expired - Fee Related
- 2003-05-15 AU AU2003230245A patent/AU2003230245A1/en not_active Abandoned
- 2003-05-15 HU HU0501016A patent/HUP0501016A2/hu unknown
- 2003-05-15 IL IL16501203A patent/IL165012A0/xx unknown
- 2003-05-15 RU RU2004136853/04A patent/RU2004136853A/ru not_active Application Discontinuation
- 2003-05-15 KR KR10-2004-7018158A patent/KR20040107520A/ko not_active Withdrawn
- 2003-05-15 MX MXPA04011332A patent/MXPA04011332A/es unknown
- 2003-05-15 AR ARP030101702A patent/AR040021A1/es unknown
- 2003-05-15 CN CNA03811089XA patent/CN1653063A/zh active Pending
- 2003-05-15 SK SK5019-2004A patent/SK50192004A3/sk unknown
- 2003-05-15 CZ CZ20041084A patent/CZ20041084A3/cs unknown
- 2003-05-15 PL PL03372724A patent/PL372724A1/xx not_active Application Discontinuation
- 2003-05-15 TR TR2004/03020T patent/TR200403020T2/xx unknown
- 2003-05-15 WO PCT/JP2003/006051 patent/WO2003097638A1/en not_active Ceased
-
2004
- 2004-11-09 ZA ZA200409035A patent/ZA200409053B/en unknown
- 2004-12-15 NO NO20045469A patent/NO20045469L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK50192004A3 (sk) | 2005-04-01 |
| ZA200409053B (en) | 2005-07-12 |
| MXPA04011332A (es) | 2005-02-14 |
| JP2004043453A (ja) | 2004-02-12 |
| TW200400186A (en) | 2004-01-01 |
| HUP0501016A2 (en) | 2006-02-28 |
| KR20040107520A (ko) | 2004-12-20 |
| EP1362857B1 (en) | 2004-08-11 |
| DK1362857T3 (da) | 2004-12-20 |
| DE60300021T2 (de) | 2005-09-08 |
| RU2004136853A (ru) | 2005-06-27 |
| PT1362857E (pt) | 2004-11-30 |
| CZ20041084A3 (cs) | 2005-02-16 |
| HK1060118A1 (en) | 2004-07-30 |
| US20030216433A1 (en) | 2003-11-20 |
| EP1362857A1 (en) | 2003-11-19 |
| JP3643107B2 (ja) | 2005-04-27 |
| IL165012A0 (en) | 2005-12-18 |
| TR200403020T2 (tr) | 2005-05-23 |
| CA2483368A1 (en) | 2003-11-27 |
| ES2227500T3 (es) | 2005-04-01 |
| ATE273304T1 (de) | 2004-08-15 |
| PL372724A1 (en) | 2005-07-25 |
| NO20045469L (no) | 2005-02-16 |
| CN1653063A (zh) | 2005-08-10 |
| WO2003097638A1 (en) | 2003-11-27 |
| US6696468B2 (en) | 2004-02-24 |
| DE60300021D1 (de) | 2004-09-16 |
| BR0309933A (pt) | 2005-02-09 |
| AU2003230245A1 (en) | 2003-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040021A1 (es) | (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetrahidrofuril-carbonil)-4-piperidinilmetil]-4-piperidinil]benzamida, procedimiento para su preparacion, composicion farmaceutica que la contiene, e intermediarios para su preparacion | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| MX2020009928A (es) | Compuestos organicos. | |
| CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
| BR0312975A (pt) | Forma cristalina de agonista de receptor adrenérgico ß2 | |
| EP2269608A3 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | |
| NO20075920L (no) | Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria | |
| AR004158A1 (es) | Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto. | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| DE602004024383D1 (de) | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists | |
| EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
| PE20040767A1 (es) | Derivado hemisulfato de azido citosina cristalino anhidro | |
| UY38055A (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario | |
| CA2406266A1 (en) | A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds | |
| ATE318266T1 (de) | 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten | |
| WO2023178113A3 (en) | Organic compounds | |
| WO2023178111A3 (en) | Organic compounds | |
| PE20070521A1 (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a | |
| EA200701687A1 (ru) | Гидрохлорид аморфного лерканидипина | |
| BR0318242A (pt) | derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação | |
| DK1566173T3 (da) | Farmaceutisk sammensætning til oral anvendelse og fremgangsmåde til fremstilling deraf | |
| NO20060191L (no) | 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister | |
| DE60214830D1 (de) | C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen | |
| PE20080923A1 (es) | Forma cristalina polimorfica qalfa de maleato de (r)-5-[2-(5,6-dietil-indan-2-il-amino)-1-hidroxi-etil]-8-hidroxi-1h-quinolin-2-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |